Educational Research PlatformUpgrade Your Biology at Its Core
Peptide, mitochondrial, metabolic, repair, and longevity science explained through public research, clinical studies, regulatory context, and safety-focused education.
- Peptide Profiles
- 101
- Sourced References
- 617
- Human Studies
- 307
- Preclinical Research
- 156
- Regulatory Sources
- 154
- Reviews
- 76
- Anecdotal Reports
- 0
Research Categories
Educational summaries are organized by research area to help you find relevant public science quickly.
Metabolic
Weight, glucose, and metabolic-pathway research.
Mitochondrial
Cellular energy and mitochondrial signaling.
Repair
Tissue, soft-tissue, and wound-healing research.
GH / Body Composition
Growth-hormone axis and body-composition studies.
Cognitive
Neuro and cognitive-performance research topics.
Hormone Support
Endocrine and hormone-pathway education.
Featured Peptides
Educational research profiles covering mechanism context, evidence grade, and safety considerations.
Retatrutide
Retatrutide is an investigational triple agonist designed to activate GIP, GLP-1, and glucagon receptors. It is being studied mainly for obesity, type 2 diabetes, liver fat/MASLD, and obesity-related complications. Its strongest evidence comes from human clinical trials, but long-term safety, regulatory approval, and real-world product quality remain unresolved.
View research profile →Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing hormone analog that increases endogenous GH release and downstream IGF-1. Its strongest human evidence is reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It is also studied for liver fat in people with HIV, but broad anti-aging or bodybuilding uses should be treated as off-label and much less established.
View research profile →Ipamorelin
Ipamorelin is a growth hormone secretagogue that activates the ghrelin/GHS receptor and is discussed for GH-pulse support, recovery, sleep, and body composition. Compared with older GHRPs, it is often described as more selective, but strong human outcome data for wellness uses are limited. Most consumer-facing uses are anecdotal or clinic-driven rather than supported by large controlled trials.
View research profile →An Evidence-Graded System
Every peptide profile is assigned an evidence grade so you can see at a glance how much human clinical support exists before reading further.
Strong human clinical evidence, often within an approved indication.
Meaningful human clinical trial evidence; approval or long-term data may still be pending.
Mixed or limited human evidence; largely clinic or early-stage context.
Mostly preclinical or anecdotal; human outcome data is limited.
Minimal controlled evidence of any kind; primarily community/anecdotal interest.
The grade evaluates the evidence supporting the specific category or claim. Evidence strength can differ by indication or research question, which is why some profiles show more than one grade. How MitoCore grades evidence →
Source Types We Separate
- Human Studies & Clinical Data
- Animal / Cell / Preclinical Data
- Regulatory Documents & Official Trial Registries
- Review Articles / Secondary Sources
- Anecdotal Reports
- MitoCore Editorial Search Audits
Latest Research
New studies, regulatory developments, and MitoCore research updates.
Phase 3 ESSENCE Trial Finds Semaglutide Improves Liver Histology in MASH With Fibrosis
This is the first large Phase 3 trial to report semaglutide's effect on liver biopsy outcomes in MASH specifically, rather than on weight or glycemic measures. It moves semaglutide's evidence base for a liver-specific indication from smaller Phase 2 data into a large, randomized, biopsy-confirmed Phase 3 setting -- a materially stronger form of evidence than the Phase 2 trials this compound was previously evaluated on for this indication.
FDA Advisory Panel Narrowly Votes to Recommend BPC-157 for Compounding Access
This is a regulatory-access development, not a scientific or safety finding. A PCAC recommendation determines whether compounding pharmacies may legally prepare a substance -- it is not an FDA approval, and it does not itself establish that BPC-157 is safe or effective for any human use. The vote is advisory only; the FDA is not bound by it and must still issue its own final decision.
Retatrutide TRIUMPH-4 Topline Results Report 28.7% Average Weight Loss in Obesity With Knee Osteoarthritis
TRIUMPH-4 is one of eight pivotal Phase 3 trials in Lilly's TRIUMPH program for retatrutide. This readout is notable both for the reported magnitude of weight loss and because it is the first retatrutide Phase 3 trial to report a musculoskeletal/pain outcome (knee osteoarthritis symptoms) alongside weight loss, rather than a purely metabolic or weight endpoint.
Safety-First by Design
MitoCore is built to educate, not to prescribe, sell, or promote. Safety context sits alongside every research summary.
Read Safety & Quality- Every dosing reference is labeled as Study / Trial Dosing or Anecdotal Reported Patterns — never as a recommendation.
- Negative findings and safety signals are documented alongside benefits being studied, not hidden.
- Regulatory status is stated plainly, including investigational and non-approved compounds.
- Community reports, when enabled, will appear only as moderated, anonymized, aggregated data.
Study Database
Search and filter the full research index by peptide, evidence category, source type, or year — every record separated by how it was studied.
Help Build a Safer Peptide Knowledge Base
Share anonymous experience data about peptide use, reported dosing patterns, duration, perceived benefits, side effects, stacks, and tracked labs. Community reports are anecdotal and not medical advice.
You can preview the community experience questionnaire now, but this is a front-end preview only — no real submissions are stored yet, and nothing here is medical advice.